HighTower Advisors
AGIO icon

HighTower Advisors’s Agios Pharmaceuticals AGIO Stock Holding History

HighTower Advisors’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-3,276
Closed -$222K – 2060
2015
Q4 		$222K Buy
+3,276
New +$215K ﹤0.01% 1703

Other funds holding AGIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
FVF2
Flagship Ventures Fund 2007 Cambridge, Massachusetts $95.2M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

HighTower Advisors's AGIO Position: Q1 2016 in Review

HighTower Advisors sold out of Agios Pharmaceuticals (AGIO) in Q1 2016, closing a stake of 3,276 shares — an estimated $222K sold.

HighTower Advisors first reported a position in AGIO in Q4 2015 and held it in 1 quarter. The position peaked at $222K in Q4 2015. 156 funds tracked by Wall St. Rank hold AGIO as of Q1 2016.

  • HighTower Advisors reported no remaining Agios Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • HighTower Advisors sold 3,276 Agios Pharmaceuticals shares in Q1 2016, an estimated $222K.
  • HighTower Advisors first reported a position in Agios Pharmaceuticals in Q4 2015 and held it in 1 quarter.
  • HighTower Advisors's Agios Pharmaceuticals position peaked at $222K in Q4 2015.
  • 156 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q1 2016.

Based on HighTower Advisors's 13F filing for Q1 2016, filed 16 May 2016.